Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
about
Retrospective analysis of safety and feasibility of a 3 days on/11 days off temozolomide dosing regimen in recurrent adult malignant gliomasDevelopment of a new UPLC-MSMS method for the determination of temozolomide in mice: application to plasma pharmacokinetics and brain distribution study.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.What is the role of chemotherapy in the treatment of melanoma?A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m(2) (Dralitem(®) vs. Temodal(®) Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions.In Vitro Radiosensitizing Effects of Temozolomide on U87MG Cell Lines of Human Glioblastoma Multiforme.In situ electrochemical evaluation of anticancer drug temozolomide and its metabolites-DNA interaction.Formulation and statistical optimization of intravenous temozolomide-loaded PEGylated liposomes to treat glioblastoma multiforme by three-level factorial design.Success at last: a molecular factor that informs treatment.Irinotecan and temozolomide brain distribution: a focus on ABCB1.Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.Glioblastoma Treatments: An Account of Recent Industrial Developments
P2860
Q34426355-0C9B0109-4F13-44CF-B1D8-092D34DDFF79Q34597636-0EFD0355-EB05-4751-AE97-7369838A0293Q38082728-99697187-89F7-404C-AA82-BEEF3CEE6B61Q38193716-267A9CFA-1F95-4FBF-9845-3C8B9DF4F922Q38373115-9AEE9A3D-33B0-40F4-8B84-60EAF44D0454Q38769884-BC901331-0A39-47FB-BA1B-AB6BDA13CC88Q43792451-3DC32020-706F-4180-8DCE-CD397B31F018Q47894210-72E08B5A-2290-4D33-BA1C-34860A9F255BQ48250296-D0CCADC2-0013-47C1-A708-84C661007958Q48761910-2F2B9FD5-F75A-4619-9BA8-06837DDBF581Q49093789-E091B48D-D217-4645-ADF6-6698634CBB50Q57111067-F0EDA711-3B56-4562-9A23-FA030C4BE483
P2860
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@ast
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@en
type
label
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@ast
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@en
prefLabel
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@ast
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@en
P2093
P2860
P1476
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
@en
P2093
Bhavna Kantesaria
Blanca D Diez
David Cutler
Fabio H Ottaviano
Fengjuan Xuan
Malaz A Abutarif
Marc Cantillon
Maria Guadalupe Pallotta
Max Schwarz
Paul Statkevich
P2860
P2888
P304
P356
10.1007/S00280-009-1078-6
P577
2009-07-30T00:00:00Z
P5875
P6179
1029347289